Press Releases | Regeneron Pharmaceuticals Inc.
WEBLibtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer. Sep 9. Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO. Aug 26.
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Regeneron and Mammoth Biosciences Collaborate to Pursue …
WEBTARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types.
Regeneron Announces Encouraging Topline Phase 2 Data of High …
WEBAug 24, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® (aflibercept) Injection in patients with …
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
WEB4 days ago · The latest approval expands the initial FDA approval (granted in June 2019) in CRSwNP for patients aged 18 years and older. Regeneron’s shares have rallied 31.3% year to date compared to the ...
Regeneron Announces New U.S. Government Agreement to …
WEBUnder the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022, at a cost of $2,100 per dose. This new agreement follows two earlier agreements with the U.S. government announced in July 2020 and January 2021.
News Release - Regeneron Pharmaceuticals Inc.
WEBSep 10, 2022 · Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors. First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer.
Regeneron Pharmaceuticals: Delivering Life-transforming Medicines
WEBRegeneron News: Sep 13th. Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Regeneron Pharmaceuticals, Inc. (REGN) Latest Stock News
WEBGet the latest Regeneron Pharmaceuticals, Inc. (REGN) stock news and headlines to help you in your trading and investing decisions.
Regeneron's COVID antibody drug shows protection for up to 8 …
WEBNov 8 (Reuters) - Regeneron Pharmaceuticals Inc (REGN.O) said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two...